- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2019 (adjunctive TRD) and expanded to monotherapy in January 2025.
- Why 4/10
- Spravato is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout in the next ~12 months. The next hard, dated catalyst is not a binary regulatory event but continued commercial execution; therefore the impact score is capped at 4.
Spravato is a steady growth contributor within JNJ's broader Innovative Medicine segment, not a binary catalyst for the stock. Watch for quarterly sales trends as a read on commercial adoption, and monitor the COMP360 psilocybin NDA (submitted November 2026) as potential future competition in the treatment-resistant depression space.
Price Chart
Executive Summary
Spravato (esketamine) is Johnson & Johnson's FDA-approved nasal spray for treatment-resistant depression (TRD). Originally approved in 2019 as an add-on therapy with an oral antidepressant, it received a major label expansion in January 2025 as the first and only monotherapy for TRD. The drug is a Schedule III controlled substance administered in a healthcare setting under a REMS program due to sedation and dissociation risks. Spravato has shown consistent quarter-over-quarter sales growth and is considered a growth driver in JNJ's neuroscience portfolio. In September 2026, JNJ's Janssen subsidiary won a patent infringement case against Sandoz, protecting the drug from generic competition. However, competition is emerging: Compass Pathways submitted an NDA for COMP360 psilocybin for TRD in November 2026, which could become the first FDA-approved classic psychedelic. For JNJ, a $100B+ revenue company, Spravato is a meaningful but not dominant product.
How It Works
Spravato (esketamine) is a nasal spray form of a ketamine-like drug. It works differently from standard antidepressants by blocking a brain receptor called NMDA, which rapidly increases levels of glutamate, a chemical that helps brain cells communicate. This can quickly improve mood in people with depression that has not responded to other treatments.
Trial Status
Spravato is FDA-approved and commercially available. Real-world evidence studies (ECHO cohort, 570 patients across Europe and Israel) have shown robust effectiveness and durable effect in treatment-resistant depression. The VA began administering Spravato to eligible veterans.
The Two-Sided Case
Upcoming Catalysts
- Continued quarterly sales growth trajectory as a read on commercial adoption of the monotherapy label.
- Compass Pathways' COMP360 psilocybin NDA review timeline (submitted Nov 2026) as a potential competitive threat.
- Any further label expansion or new indication studies for esketamine.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report